Ftse Mib
33.573,49
-0,40%
DAX
18.165,45
0,02%
S&P 500
5.459,46
-0,18%
NASDAQ
17.741,39
0,13%
Bitcoin
61.391,19
-0,68%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lexaria Bioscience Corporation (LEXXW) Lexaria Bioscience Corporation (LEXXW) Notizie

LEXXW

Lexaria Bioscience (LEXXW)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LEXXW
DataOraFonteTitoloSimboloCompagnia
12/06/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXWLexaria Bioscience Corporation
11/06/202423:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LEXXWLexaria Bioscience Corporation
03/06/202419:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LEXXWLexaria Bioscience Corporation
15/05/202423:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXWLexaria Bioscience Corporation
22/07/202114:18InvestorsHub NewsWireLexaria Summarizes Successful Antiviral Drug Studies and Ongoing StrategyNASDAQ:LEXXWLexaria Bioscience Corporation
21/07/202113:27InvestorsHub NewsWireLexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3NASDAQ:LEXXWLexaria Bioscience Corporation
15/07/202114:14InvestorsHub NewsWireLexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research CouncilNASDAQ:LEXXWLexaria Bioscience Corporation
03/06/202114:05InvestorsHub NewsWireLexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 VirusNASDAQ:LEXXWLexaria Bioscience Corporation
20/05/202113:16InvestorsHub NewsWireLexaria's Newest DehydraTECHTM 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption..contNASDAQ:LEXXWLexaria Bioscience Corporation
12/05/202113:18InvestorsHub NewsWireLexaria Strengthens its International Patent Portfolio to 19 Patents GrantedNASDAQ:LEXXWLexaria Bioscience Corporation
06/05/202113:35InvestorsHub NewsWireLexaria Issues Successful Results from First 2021 Study, HYPER-A21-1NASDAQ:LEXXWLexaria Bioscience Corporation
14/04/202113:37InvestorsHub NewsWireLexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope NetworkNASDAQ:LEXXWLexaria Bioscience Corporation
06/04/202113:16InvestorsHub NewsWireLexaria to Evaluate DehydraTECHTM in Multiple New MarketsNASDAQ:LEXXWLexaria Bioscience Corporation
24/03/202113:00InvestorsHub NewsWireLexaria Technology Generates Positive Stability Testing for World-Class Ready to Drink CBD BeveragesNASDAQ:LEXXWLexaria Bioscience Corporation
16/03/202112:39InvestorsHub NewsWireLexaria's Antiviral Drug Evaluation Program ProgressingNASDAQ:LEXXWLexaria Bioscience Corporation
15/03/202113:30InvestorsHub NewsWireRapid Progress in Hypertension Studies by LexariaNASDAQ:LEXXWLexaria Bioscience Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LEXXW

La tua Cronologia

BIT
F13669
Vontobel Financial Produ...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network